SDC1 and dengue disease: Evidence of reduced glycocalyx thickness together with increased plasma concentrations of EGL fragments, such as Syndecan-1, Heparan Sulfate, and Hyaluronan, in dengue patients suggests these products may be useful biomarkers and surrogates of leakage severity [5, 6].